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INTRODUCTION:  Although  it is  well-known  that in multiple  endocrine  neoplasia  type  1 (MEN  1)  dis-
ease,  multiple  endocrine  lesions  frequently  occur,  synchronous  or metachronous  neuroendocrine  tumors
(NETs) in non-MEN  1 patients  are  extremely  rare.
PRESENTATION  OF  CASE:  An  asymptomatic  72-year-old  woman  with  an  ileal  NET  was referred  to our
hospital.  Abdominal  computed  tomography  revealed  another  circular  tumor  within  the  pancreatic  head.
She was  classiﬁed  as  a non-MEN  1 patient.  An  operative  procedure  was  performed  with  a  preoperative
diagnosis  of synchronous  NET,  which  was  conﬁrmed  by pathological  examination.leum
ase report
DISCUSSION:  Both  morphologic  and  immunophenotypic  ﬁndings  were  different  between  in the ileum
and  pancreas.  Therefore,  it was  reasonable  to consider  that both  tumors  were  primary  tumors.  The
synchronous  occurrence  of  these  tumors  is  unusual,  and it  may  be considered  as  a chance  occurrence.
CONCLUSION:  We  here  report  the  ﬁrst  case  of  synchronous  pancreatic  NET  and  ileal  NET  in  a  non-MEN  1
patient.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
ccount for approximately 2% of all neoplasms [1,2]. Although it
s well-known that in multiple endocrine neoplasia type 1 (MEN
) disease, multiple endocrine lesions in the pituitary, parathy-
oid, and embryological foregut organs (lung, stomach, duodenum,
pper jejunum, and pancreas) frequently occur [3], synchronous
r metachronous NETs in non-MEN 1 patients are extremely rare.
o the best of our knowledge, no case of synchronous NETs in
on-MEN 1 disease has been previously reported in the English
iterature. Here we present the ﬁrst case of synchronous pancreatic
ET (PNET) and ileal (midgut) NET in a non-MEN 1 patient.
. Presentation of the caseA 72-year-old woman was found to have an ileal polypoid
umor by colonoscopy, which was performed because of posi-
∗ Corresponding author.
E-mail address: suaosasa@ndmc.ac.jp (S. Aosasa).
ttp://dx.doi.org/10.1016/j.ijscr.2016.03.028
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Gro
http://creativecommons.org/licenses/by-nc-nd/4.0/).tive results from an occult blood test of the stool. Histology of
the biopsy specimens taken from the tumor revealed it was a
NET. The patient was referred to our hospital. On admission,
she did not have any symptoms. Her medical and family his-
tory was unremarkable. The laboratory ﬁndings were as follows:
white blood cell count = 5600/l,  hemoglobin = 12.2 g/dl, hemat-
ocrit = 35.6%, platelets = 235 × 103/l, aspartate aminotransferase
(AST) = 15 IU/l (normal <30), alanine aminotransferase (ALT) = 15
IU (normal <35), and amylase = 64 IU/l (normal <132). HbA1c was
7.1%, suggestive of a mild glucose intolerance. The tumor-markers
were within normal limits. Her insulin level was slightly elevated at
18.7 U/ml (1.1–9.0), but gastrin level was  within the normal ranges
(190 pg/ml; normal <200). Neither pituitary tumor nor parathy-
roid tumor were detected. Dynamic contrast-enhanced computed
tomography (CT) revealed another enhanced round mass within
the pancreatic head, in addition to the ileal tumor. On  dynamic
contrast-enhanced magnetic resonance imaging (MRI), the pancre-
atic mass showed rapid contrast enhancement at arterial phase
on the fat suppression T1-weighted image. Fluorodeoxyglucose
positron emission tomography-CT (FDG-PET/CT) showed abnor-
mal  ﬂuorodeoxyglucose-uptake in both lesions of the pancreas
and ileum alone, without evidence of other metastatic deposits
up Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Computed tomography (CT), magnetic resonance imaging (MRI), and ﬂuorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) images.
(a)  arterial phase of dynamic CT revealed the enhanced tumor measuring 20 × 15 mm in size located in the head of the pancreas. (b) portal phase of dynamic CT also revealed
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she  enhanced tumor measuring 20 × 20 mm in size. (c) arterial phase of dynamic MR
bnormal uptake only in the pancreas and the ileocecal lesions.
r endocrine lesions (Fig. 1). A subtotal stomach-preserving pan-
reaticoduodenectomy and an ileocecal resection were performed
imultaneously. The duration of the operation was 9 h and 15 min
nd the total amount of blood loss was 322 ml.
In the resected specimens, a whitish solid-nodular tumor in
he pancreas head, measuring 14 × 13 × 12 mm size, and a yel-
owish solid-protruding tumor in the terminal ileum, measuring
1 × 7 × 15 mm size were found (Fig. 2). Histologically, both tumors
ere composed of relatively monotonous growth of tumor cells
ith round nuclei. The tumor cells in the pancreas proliferated
n small-size cell-nests and had thin trabecular architectures. The
umor cells in the ileum proliferated in round cell-nests and
umor cells tended to have a palisade periphery. Both tumors
ere immunohistochemically positive for neuroendocrine mark-
rs (i.e., chromogranin A, synaptophysin, and CD56), and negative
or insulin, glucagon, somatostatin, and gastrin. However, sero-
onin was positive only in the ileal tumor alone, whereas pancreatic
olypeptide (PP) positivity was only observed in the pancreas
umor (Fig. 2). The Ki-67 labeling indexes of both tumors were
elow 2%. The ileal tumor had a metastatic deposit in a regional
ymph node. From the morphologic and immunophenotypic dif-
erences, these tumors were considered to be both primary NETs
1, according to the WHO  2010 classiﬁcation [4]. The pancreatic
umor was categorized as a non-functional PNET (so-called PP-
ma), pT2, pN0, M0,  pStage Ib, and the ileal tumor categorized as an
nterochromafﬁn (EC) cell, serotonin-producing NET (previously
esignated EC cell-midgut carcinoid), pT2, pN1, M0,  pStage IIIb.
The patient’s post-operative course was uneventful, and the
atient has been free from tumor recurrence for 20 months since
urgery without any adjuvant therapy.ed the rapid enhanced tumor in the head of the pancreas. (d) FDG-PET/CT revealed
3. Discussion
The incidence rate of GEP-NETs in the United States increased
ﬁve-fold (from 1.09 per 100,000 people to 5.25 per 100,000) from
1973 to 2004 [5]. A similar tendency in the incidence of GEP-NETs
was observed in Japan [6]. In the near future, with advances in both
practitioner knowledge and imaging technology, synchronous or
metachronous such as that demonstrated here, may be reported
more often. At the initial diagnosis, 19.9% of PNETs patients and
6.0% of GI-NETs patients were reported to have distant metastasis
[6]. Although the liver is the predominant site for NETs metastases
[7,8], the present case did not show liver metastasis. Furthermore,
both morphologic and immunophenotypic ﬁndings were different
between in the ileum and pancreas. Therefore, we  believe it was
reasonable to consider that both tumors were primary tumors.
Some GEP-NETs may  be associated with genetic syndromes,
particularly MEN  1 [6,9,10]. Non-functioning PNETs and gastric
(foregut) NETs have been observed in 20% and 10% of MEN 1
patients at age 40 years, respectively [11]. However, EC cell,
serotonin-producing NETs, which were observed in the present
case, were not consistent the sequence of MEN 1 pathogenesis
[3,6,12]. In non-MEN patients, synchronous or metachronous NETs
in the plural embryologic regions have not been reported in the
literature, although EC cell, multiple serotonin-producing NETs
can occur within the midgut [13]. Moreover, differences between
gene expression proﬁles of PNETs and those of EC cell serotonin-
producing NETs in recent studies [14,15] suggested that these
NETs did not share the same tumorigenic pathway. Thus, the syn-
chronous occurrence of a PNET and GI-NET observed in the present
case may  be a coincidental ﬁnding.
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Fig. 2. Gross and microscopic features of pancreatic and ileal tumors. (a) The pancreatic tumor was  observed as a gray-whitish round mass (arrows) on the excised surfaces.
(b)  The ileal tumor exhibited a yellowish polypoid tumor. (c) Relatively small-sized nests of tumor cells were observed in the pancreatic tumor. (d) Rounded nests of tumor
cells  with peripheral palisading were observed in the ileal tumor. (e, f) On immunohistochemistry, the tumor cells of both the pancreas (e) and ileum (f) were positive for
synaptophysin. (g) The tumor cells of the pancreas were positive for pancreatic polypeptide. (h) The tumor cells of the ileum were positive for serotonin.Scale bars in (a) and
(b)  indicated 1 cm;  (c, d) Hematoxylin-Eosin, x200; and (e–h) Immunohistochemistry with diaminobenzithin, x200.
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. Conclusion
We  herein report the ﬁrst case of synchronous NETs in both the
ancreas and ileum. The synchronous occurrence of these tumors
s unusual, and it may  be considered as a chance occurrence.
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